Federal vaccine advisors hand-selected by anti-vaccine Health Secretary Robert F. Kennedy Jr. have voted to eliminate a recommendation that all babies be vaccinated against hepatitis B on the day of birth. The decision was made with no evidence of harm from that dose and no evidence of any benefit from the delay.
Public health experts, medical experts, and even some members of the panel decried the vote, which studies and historical data indicate will lead to more infections in babies that, in turn, will lead to more cases of chronic liver disease, liver cancer, and premature death.
“I will just say we have heard ‘do no harm’ is a moral imperative. We are doing harm by changing this [recommendation],” Cody Meissner, a pediatrician and voting member of the Advisory Committee on Immunization Practices (ACIP), said as he voted against the change.
© Getty | Tim Clayton
One day this fall, I watched an electronic sign outside the Broadway-Lafayette subway station in Manhattan switch seamlessly between an ad for makeup and one promoting the website Pickyourbaby.com, which promises a way for potential parents to use genetic tests to influence their baby’s traits, including eye color, hair color, and IQ.
Inside the station, every surface was wrapped with more ads—babies on turnstiles, on staircases, on banners overhead. “Think about it. Makeup and then genetic optimization,” exulted Kian Sadeghi, the 26-year-old founder of Nucleus Genomics, the startup running the ads. To his mind, one should be as accessible as the other.
Nucleus is a young, attention-seeking genetic software company that says it can analyze genetic tests on IVF embryos to score them for 2,000 traits and disease risks, letting parents pick some and reject others. This is possible because of how our DNA shapes us, sometimes powerfully. As one of the subway banners reminded the New York riders: “Height is 80% genetic.”
The day after the campaign launched, Sadeghi and I had briefly sparred online. He’d been on X showing off a phone app where parents can click through traits like eye color and hair color. I snapped back that all this sounded a lot like Uber Eats—another crappy, frictionless future invented by entrepreneurs, but this time you’d click for a baby.
I agreed to meet Sadeghi that night in the station under a banner that read, “IQ is 50% genetic.” He appeared in a puffer jacket and told me the campaign would soon spread to 1,000 train cars. Not long ago, this was a secretive technology to whisper about at Silicon Valley dinner parties. But now? “Look at the stairs. The entire subway is genetic optimization. We’re bringing it mainstream,” he said. “I mean, like, we are normalizing it, right?”
Normalizing what, exactly? The ability to choose embryos on the basis of predicted traits could lead to healthier people. But the traits mentioned in the subway—height and IQ—focus the public’s mind toward cosmetic choices and even naked discrimination. “I think people are going to read this and start realizing: Wow, it is now an option that I can pick. I can have a taller, smarter, healthier baby,” says Sadeghi.
Nucleus got its seed funding from Founders Fund, an investment firm known for its love of contrarian bets. And embryo scoring fits right in—it’s an unpopular concept, and professional groups say the genetic predictions aren’t reliable. So far, leading IVF clinics still refuse to offer these tests. Doctors worry, among other things, that they’ll create unrealistic parental expectations. What if little Johnny doesn’t do as well on the SAT as his embryo score predicted?
The ad blitz is a way to end-run such gatekeepers: If a clinic won’t agree to order the test, would-be parents can take their business elsewhere. Another embryo testing company, Orchid, notes that high consumer demand emboldened Uber’s early incursions into regulated taxi markets. “Doctors are essentially being shoved in the direction of using it, not because they want to, but because they will lose patients if they don’t,” Orchid founder Noor Siddiqui said during an online event this past August.
Sadeghi prefers to compare his startup to Airbnb. He hopes it can link customers to clinics, becoming a digital “funnel” offering a “better experience” for everyone. He notes that Nucleus ads don’t mention DNA or any details of how the scoring technique works. That’s not the point. In advertising, you sell the sizzle, not the steak. And in Nucleus’s ad copy, what sizzles is height, smarts, and light-colored eyes.
It makes you wonder if the ads should be permitted. Indeed, I learned from Sadeghi that the Metropolitan Transportation Authority had objected to parts of the campaign. The metro agency, for instance, did not let Nucleus run ads saying “Have a girl” and “Have a boy,” even though it’s very easy to identify the sex of an embryo using a genetic test. The reason was an MTA policy that forbids using government-owned infrastructure to promote “invidious discrimination” against protected classes, which include race, religion and biological sex.
Since 2023, New York City has also included height and weight in its anti-discrimination law, the idea being to “root out bias” related to body size in housing and in public spaces. So I’m not sure why the MTA let Nucleus declare that height is 80% genetic. (The MTA advertising department didn’t respond to questions.) Perhaps it’s because the statement is a factual claim, not an explicit call to action. But we all know what to do: Pick the tall one and leave shorty in the IVF freezer, never to be born.
This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.
The panel of federal vaccine advisors hand-selected by anti-vaccine Health Secretary Robert F. Kennedy Jr. has once again punted on whether to strip recommendations for hepatitis B vaccinations for newborns—a move it tried to make in September before realizing it didn’t know what it was doing. The decision to delay the vote today came abruptly this afternoon when the panel realized it still does not understand the topic or what it was voting on.
Prior to today’s 6–3 vote to delay a decision, there was a swirl of confusion over the wording of what a new recommendation would be. Panel members had gotten three different versions of the proposed recommendation in the 72 hours prior to the meeting, one panelist said. And the meeting’s data presentations this morning offered no clarity on the subject—they were delivered entirely by anti-vaccine activists who have no subject matter expertise and who made a dizzying amount of false and absurd claims.
Overall, the meeting was disorganized and farcical. Kennedy’s panel has abandoned the evidence-based framework for setting vaccine policy in favor of airing unvetted presentations with misrepresentations, conspiracy theories, and cherry-picked studies. At times, there were tense exchanges, chaos, confusion, and misunderstandings.
© Getty | Elijah Nouvelage
Just a tiny amount of fentanyl, the equivalent of a few grains of sand, is enough to stop a person’s breathing. The synthetic opioid is tasteless, odorless, and invisible when mixed with other substances, and drug users are often unaware of its presence.
It’s why biotech entrepreneur Collin Gage is aiming to protect people against the drug’s lethal effects. In 2023, he became the cofounder and CEO of ARMR Sciences to develop a vaccine against fentanyl. Now, the company is launching a trial to test its vaccine in people for the first time. The goal: prevent deaths from overdose.
“It became very apparent to me that as I assessed the treatment landscape, everything that exists is reactionary,” Gage says. “I thought, why are we not preventing this?”
© Douglas Sacha via Getty Images
Bill Gates and the Gates Foundation are raising the alarm over the deadly impacts of international funding cuts in global health. Slashed budgets are projected to reverse decades of progress, causing the number of children dying before their fifth birthday to rise for the first time this century. An estimated 4.8 million children are expected to die this year, an increase of 200,000 deaths compared to last year.
“That is something that we hope never to report on, but it is a sad fact. And there are many causes, but clearly one of the key causes has been significant cuts in international development assistance from a number of high-income countries,” said Mark Suzman, CEO of the Gates Foundation, in a briefing with media this week.
Suzman specifically called out the U.S., the United Kingdom, France and Germany for “making significant cuts” to their support. Internationally, funding plunged 26.9% below last year’s levels, according to the philanthropy.
The Gates Foundation today released its annual Goalkeepers Report, which tracks progress on measures including poverty, hunger, access to clean water and energy, environmental benchmarks and other metrics.
The Seattle-based foundation worked with the University of Washington’s Institute for Health Metrics and Evaluation to model the effects of reduced assistance. The researchers found that if the cuts to aid persist or worsen, an additional 12 million to 16 million children could die over the next 20 years.
While offering dire projections, the document aims to be a call to action for governments and philanthropists large and small.
“This report is a roadmap to progress,” Gates writes, “where smart spending meets innovation at scale.”
The billionaire Microsoft co-founder calls out some specific areas that could yield the most benefit, including primary healthcare, routine immunizations, the development of improved vaccines and new uses of data.
Modeling in the report predicts that by 2045, better vaccines for respiratory syncytial virus (RSV) and pneumonia could save 3.4 million children, while new malaria tools could save an additional 5.7 million kids. Shots of lenacapavir could successfully prevent and treat HIV.
The foundation calls attention to the life-saving benefits of vaccinations as the U.S. Secretary of Health Robert F. Kennedy Jr. continues to undercut public support of vaccines.
With the backdrop of reduced federal funding for global humanitarian causes and backpedaling on vaccinations, Gates earlier this year announced plans to give away $200 billion — including nearly all of his wealth — over the next two decades through the Gates Foundation.
The Seattle-based organization, which celebrates its 25th anniversary this year, will sunset its operations on Dec. 31, 2045. The philanthropy is the world’s largest and has already disbursed $100 billion since its founding.
“If we do more with less now — and get back to a world where there’s more resources to devote to children’s health — then in 20 years, we’ll be able to tell a different kind of story,” Gates writes in the report. “The story of how we helped more kids survive childbirth, and childhood.”
On Friday, Vinay Prasad—the Food and Drug Administration’s chief medical and scientific officer and its top vaccine regulator—emailed a stunning memo to staff that quickly leaked to the press. Without evidence, Prasad claimed COVID-19 vaccines have killed 10 children in the US, and, as such, he announced unilateral, sweeping changes to the way the agency regulates and approves vaccines, including seasonal flu shots.
On Wednesday evening, a dozen former FDA commissioners, who collectively oversaw the agency for more than 35 years, responded to the memo with a scathing rebuke. Uniting to publish their response in the New England Journal of Medicine, the former commissioners said they were “deeply concerned” by Prasad’s memo, which they framed as a “threat” to the FDA’s work and a danger to Americans’ health.
In his memo, Prasad called for abandoning the FDA’s current framework for updating seasonal flu shots and other vaccines, such as those for COVID-19. Those updates currently involve studies that measure well-characterized immune responses (called immunobridging studies). Prasad dismissed this approach as insufficient and, instead, plans to require expensive randomized trials, which can take months to years for each vaccine update.
© Getty | Joe Raedle
Hidden code in ChatGPT’s iOS app hints that a Health-app connector is incoming, giving AI-powered chat a full view of your activity, sleep, and fitness stats.
The post You could soon ask ChatGPT how healthy your week really was appeared first on Digital Trends.
The top drug regulator at the Food and Drug Administration, Richard Pazdur, has decided to retire from the agency just three weeks after taking the leading position, according to multiple media outlets.
Pazdur, an oncologist who has worked at the FDA since 1999, was seen as a stabilizing force for an agency that has been mired in turmoil during the second Trump administration. He took over the role of leading the FDA’s Center for Drug Evaluation and Research on November 11, after the previous leader, George Tidmarsh, left the agency amid an investigation and a lawsuit regarding allegations that he used his position to exact petty revenge on a former business partner. In light of the scandal, one venture capital investor called the agency a “clown show.” Drug industry groups, meanwhile, called the FDA erratic and unpredictable.
Pazdur’s selection was seen as a positive sign by agency insiders, drug industry representatives, and patient advocacy groups, according to reporting by The Washington Post.
© Getty | Congressional Quarterly
Login